No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
REPL240621C10000
- 0.10
- -0.30-75.00%
15min DelayClose Jun 14 15:59 ET
0.60High0.10Low
0.60Open0.40Pre Close25 Volume193 Open Interest10.00Strike Price541.00Turnover180.26%IV20.74%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.2603Delta0.1658Gamma30.42Leverage Ratio-0.0528Theta0.0003Rho7.92Eff Leverage0.0035Vega
Intraday
- 5D
- 1D
News
Express News | Replimune Shares Are Trading Higher After the Company Announced a Private Placement Financing With an Institutional Investor for Gross Proceeds of Approximately $100 Million
Express News | Replimune Announces Private Placement Financing With An Institutional Investor For Gross Proceeds Of ~$100M
Express News | Replimune Group Inc: Proceeds Enable Full Commercial Scale up to Support a Potential Launch in 2H 2025
Express News | Replimune Announces $100 Million Private Placement Financing
Replimune(REPL.US) Officer Sells US$119.11K in Common Stock
$Replimune(REPL.US)$ Officer Xynos Konstantinos sold 15,881 shares of common stock on Jun 7, 2024 at an average price of $7.5 for a total value of $119.11K.Source: Announcement What is statement of ch
Express News | Replimune Group Inc : JP Morgan Cuts Target Price to $17 From $19
Comments
$Replimune(REPL.US$ Replimune: Positive Topline Primary Analysis Data by Independent Central Review From Ignyte Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma! Intends to submit BLA in 2H 2024
$Replimune(REPL.US$
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune presented positive data from its RP1 and RP2 clinical programs at the 2024 ASCO Annual Meeting. The IGNYTE trial showed a 32.7% overall response rate (ORR) for RP1 plus nivolumab in anti-PD-1 failed melanoma, with responses lasting over six months and a median duration exceeding 36 months. RP2, both as monotherapy and in co...
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune presented positive data from its RP1 and RP2 clinical programs at the 2024 ASCO Annual Meeting. The IGNYTE trial showed a 32.7% overall response rate (ORR) for RP1 plus nivolumab in anti-PD-1 failed melanoma, with responses lasting over six months and a median duration exceeding 36 months. RP2, both as monotherapy and in co...
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
Read more